Bamlanivimab + Etesevimab Therapy Induces SARS-CoV-2 Immune Escape Mutations and Secondary Clinical Deterioration in COVID-19 Patients with B-cell Malignancies - Sorbonne Université
Journal Articles Annals of Oncology Year : 2021

Bamlanivimab + Etesevimab Therapy Induces SARS-CoV-2 Immune Escape Mutations and Secondary Clinical Deterioration in COVID-19 Patients with B-cell Malignancies

Domains

Human health and pathology
Fichier principal
Vignette du fichier
main.pdf (310.09 Ko) Télécharger le fichier
Origin Publisher files allowed on an open archive

Aude Jary  : Connect in order to contact the contributor

https://hal.sorbonne-universite.fr/hal-03793520

Submitted on : Friday, September 6, 2024-11:11:25 AM

Last modification on : Friday, September 6, 2024-11:30:51 AM

Download

Dates and versions

hal-03793520 , version 1 (06-09-2024)

Identifiers

Cite

F. Pommeret, J. Colomba, C. Bigenwald, A. Laparra, S. Bockel, et al.. Bamlanivimab + Etesevimab Therapy Induces SARS-CoV-2 Immune Escape Mutations and Secondary Clinical Deterioration in COVID-19 Patients with B-cell Malignancies. Annals of Oncology, 2021, 32 (11), pp.1445--1447. ⟨10.1016/j.annonc.2021.07.015⟩. ⟨hal-03793520⟩

Export

BibTeX XML-TEI Dublin Core DC Terms EndNote DataCite

Collections

CNRS UNIV-AMU UNIV-FCOMTE FNCLCC IGR PAOLI_CALMETTES IPLESP SORBONNE-UNIVERSITE CRCM SU-MEDECINE
48 View
3 Download

Altmetric

Share

More